-
Cost-Effectiveness of Rozanolixizumab vs. Efgartigimod in the Treatment of Generalized Myasthenia Gravis (gMG) in Greece
Sep 9, 2025, 16:22 PM -
Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?
Sep 9, 2025, 16:22 PM -
Thecosystem: A Systemwide Health and Social Care Decision Analytical Model to Assess Population-Based Interventions for Older People’s Care in the UK
Sep 9, 2025, 16:22 PM -
Analytical Modeling in Economic Evaluations of Obesity Interventions to Inform Health Policy: A Narrative Review
Sep 9, 2025, 16:22 PM -
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Among Adolescents Aged 10-18 in China
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Coblation Intracapsular Tonsillectomy in the Management of Sleep-Disordered Breathing and Recurrent Tonsillitis: A Brazilian Perspective
Sep 9, 2025, 16:22 PM -
Projected Rapid-Growing Economic Burden of Chronic Respiratory Multimorbidity in Singapore: Unveiling Diagnostic Gaps and Asian Phenotypes Through Health Administrative Data
Sep 9, 2025, 16:22 PM -
Cost-Consequence and Clinical Impact of NGS Testing in Advanced Lung Adenocarcinoma: Real-World Evidence From a Portuguese Public Hospital
Sep 9, 2025, 16:22 PM -
Patterns of Treatment Adherence and Administration Preferences for People With Transthyretin Amyloid Cardiomyopathy: A Real-World Survey in Europe, the United States, and Japan
Sep 9, 2025, 16:22 PM -
Importance of Decisional Context in the Health Technology Assessment (HTA) of Advanced Therapy Medicinal Products (ATMPs)
Sep 9, 2025, 16:22 PM -
Quantifying the Fiscal Value of Prevention Programs for Depression
Sep 9, 2025, 16:22 PM -
Mobility and Upper Extremity Function in Duchenne Muscular Dystrophy: A Longitudinal Survey Using PROMIS
Sep 9, 2025, 16:22 PM -
The Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients With Early Breast Cancer
Sep 9, 2025, 16:22 PM -
Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Sep 9, 2025, 16:22 PM -
The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece
Sep 9, 2025, 16:22 PM -
What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?
Sep 9, 2025, 16:22 PM -
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data
Sep 9, 2025, 16:22 PM -
A Comparative Analysis of Early Access Pathways in Italy and France: Law 64896 vs. the French AAP
Sep 9, 2025, 16:22 PM
